Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring 24% higher at 11:45 a.m. EDT today.
Since licensing its hepatitis C clinical-drug pipeline to Johnson & Johnson (NYSE: JNJ) in 2015, Achillion Pharmaceuticals has been knee-deep in developing new therapies for other indications. Yesterday afternoon, the company shared with investors its second-quarter performance and its clinical-stage pipeline progress.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Stock
€235.30
0.450%
The stock is an absolute favorite of our community with 57 Buy predictions and no Sell predictions.
On the other hand, the target price of 232 € is below the current price of 235.3 € for Johnson & Johnson, so the potential is actually -1.4%.
